Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PCSK9 Inhibition & Neurocognitive Impairment

Circulation; ePub 2017 Nov 16; Mefford, et al

Exposure to low proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and cumulative exposure to lower low-density lipoprotein cholesterol (LDL-C) are not associated with neurocognitive effects in African Americans, a recent study found. The study examined the association between PCSK9 loss-of-function (LOF) variants and neurocognitive impairment and decline among African American REasons for Geographic and Racial Differences in Stroke (REGARDS) participants with (n=241) and without (n=10,454) C697X or Y142X LOF variants. Researchers found:

  • The prevalence of neurocognitive impairment at any assessment was 6.3% by Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) and 15.4% by Six Item Screener (SIS) definitions.
  • Adjusted odds ratios (ORs) for neurocognitive impairment for those with vs without PCSK9 LOF variants were 1.11 using the CERAD battery and 0.89 using the SIS assessment.
  • Patterns of neurocognitive decline were similar between participants with and without PCSK9 LOF variants.

Citation:

Mefford MT, Rosenson RS, Cushman M, et al. PCSK9 variants, LDL-cholesterol, and neurocognitive impairment: The REasons for geographic and racial differences in stroke (REGARDS) study. [Published online ahead of print November 16, 2017]. Circulation. doi:10.1161/CIRCULATIONAHA.117.029785.

This Week's Must Reads

Length of Stay & Early Discharge After Acute MI, Am J Cardiol; ePub 2017 Nov 22; Tran, et al

SBP Response and Discordant Trial Results, J Am Heart Assoc; ePub 2017 Nov 13; Huang, et al

Racial Differences in Natriuretic Peptide Levels, JAMA Cardiol; ePub 2017 Nov 22; Bajaj, et al

Gender Disparities in Cardiovascular Testing, J Am Heart Assoc; ePub 2017 Nov 29; Daugherty, et al

FDA Approves EKG Device for Apple Watch, AliveCor news release; 2017 Nov 30

Must Reads in Hypercholesterolemia

LDL-C Lowering with Evolocumab in Patients with PAD, Circulation; ePub 2017 Nov 13; Bonaca, et al

Does Evolocumab Lower Lipoprotein Particles?, Am J Cardiol; ePub 2017 Nov 8; Toth, et al

PCSK9 Inhibition & Neurocognitive Impairment, Circulation; ePub 2017 Nov 16; Mefford, et al

Eligibility for PCSK9 Inhibitors After ACS, J Am Heart Assoc; ePub 2017 Nov 9; Gencer, et al

CV Risk & Statins After MI in Young Adults, J Am Coll Cardiol; ePub 2017 Nov 14; Singh, et al